Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $36.56.

Several brokerages have weighed in on XNCR. JPMorgan Chase & Co. raised their price target on Xencor from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Piper Sandler upgraded Xencor from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research report on Thursday, September 26th. Wedbush reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. Finally, BMO Capital Markets reissued an "outperform" rating and set a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th.

Xencor Trading Down 2.9 %

XNCR stock traded down $0.73 during midday trading on Friday, reaching $24.03. The company's stock had a trading volume of 777,766 shares, compared to its average volume of 645,731. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a fifty day simple moving average of $23.03 and a two-hundred day simple moving average of $20.66. Xencor has a 1 year low of $15.31 and a 1 year high of $27.24. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -7.51 and a beta of 0.69.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the company earned ($0.40) EPS. The business's revenue was down 81.9% compared to the same quarter last year. On average, equities research analysts predict that Xencor will post -3.71 EPS for the current year.

Insider Buying and Selling at Xencor

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the business's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares of the company's stock, valued at $247,054.20. The trade was a 13.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of the business's stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares of the company's stock, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 136,050 shares of company stock worth $3,277,609. 5.23% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new stake in shares of Xencor in the third quarter worth about $540,000. Geode Capital Management LLC raised its stake in Xencor by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after buying an additional 17,658 shares in the last quarter. Barclays PLC raised its stake in Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after buying an additional 78,066 shares in the last quarter. XTX Topco Ltd raised its stake in Xencor by 113.2% during the third quarter. XTX Topco Ltd now owns 22,080 shares of the biopharmaceutical company's stock valued at $444,000 after buying an additional 11,725 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Xencor by 18.6% during the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock valued at $3,387,000 after purchasing an additional 26,473 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.